Full Press Release Details
Alterity Therapeutics Prominently Featured at
the International MSA Congress
2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints -
Index (MSAai) enhances MSA diagnosis and monitoring -
shows higher - synuclein concentration is associated with greater burden of orthostatic symptoms -
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA
- 12 May 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology
company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that several oral and poster
presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) were featured at the 2025 International MSA
Congress. The Congress was presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building
hope for people affected by MSA through support services, educational resources, research funding, and community engagement.
"The MSA Congress gave us an opportunity
to share the results of our Phase 2 double-blind trial of ATH434 with prominent MSA clinicians and scientists as well as community members
affected by MSA," said David Stamler, M.D., Chief Executive Officer of Alterity. "The robust efficacy of ATH434, as indicated
by reduced disease severity on the MSA activities of daily living scale along with improvement in key symptoms of MSA and preserved activity
in the outpatient setting, continue to generate enthusiasm. Our clinical progress is generating significant excitement, and we are focused
on bringing this therapy to patients as quickly as possible."
"In addition, our colleagues at Vanderbilt
University Medical Center presented data from our bioMUSE Natural History Study that highlights the understanding of MSA we have brought
to our development program. Because of the variability in MSA presentation and progression and its similarity to Parkinson's disease,
it is critical to improve diagnostic and monitoring tools. Through development of a novel imaging biomarker known as the MSA Atrophy Index
(MSAai), we have a new tool to measure and track brain volume in individuals with MSA. In a separate presentation, the bioMUSE study demonstrated
that -synuclein levels in the skin increased over the 12-month follow-up period, and that a higher concentration of -synuclein
in skin is associated with greater burden of orthostatic symptoms, a valuable finding that confers insight into disease progression."
Presentation Highlights:
ATH434 Slowed Disease
Progression in a Phase 2 Study in Multiple System Atrophy
Presenter: David Stamler, M.D., Chief Executive
The oral and poster presentation highlighted data
from Alterity's ATH434-201 Phase 2 clinical trial. The clinical analysis included 71 patients who had at least one post-baseline
assessment of the key clinical endpoint, the modified UMSARS1 I activities of daily living scale. On this endpoint, ATH434
demonstrated a clinically significant reduction in disease severity versus placebo, with a 48% relative treatment effect at the 50 mg
dose (p=0.02)^ and a 30% relative treatment effect at the 75 mg dose (p=0.16) at 52 weeks. Additional efficacy assessments
showed improvement consistent with the UMSARS I findings: the Clinical Global Impression of Severity Scale2 demonstrated improvement
compared to placebo at both dose levels, with difference at 50 mg achieving nominal statistical significance (p=0.0088). On the Orthostatic
Hypotension Symptom Assessment (a patient reported outcome), on average placebo patients worsened by approximately 6 points over 52 weeks
whereas both ATH434 treatment groups improved over the same period (p=0.08 at 50 mg, p=0.14 at 75 mg). Baseline differences in disease
severity likely explain different response in 50 mg and 75 mg treatment groups.
Increased activity in the outpatient setting was
observed at both dose levels as compared to placebo with wearable sensors, with clinically meaningful improvements in step count, bouts
of walking, total walking time, and total standing time. ATH434 was well tolerated with similar adverse event rates compared to placebo
and no serious adverse events attributed to ATH434. Regarding neuroimaging in 61 participants, ATH434 demonstrated target engagement by
stabilizing or reducing iron accumulation at both dose levels compared to placebo in MSA affected brain regions. In addition, ATH434 demonstrated
trends in reducing brain atrophy at both dose levels compared to placebo. Overall, the study results support continued advancement of
ATH434 for the treatment of MSA.
(MSAai): A Quantitative Imaging Marker for Diagnosis and Monitoring of Multiple System Atrophy
Presenter: Amy Brown, M.D., M.S., Assistant Professor,
Movement Disorders Division, Department of Neurology, Vanderbilt University Medical Center
This oral presentation described the MSA Atrophy
Index (MSAai) as a promising imaging biomarker that distinguishes MSA from related disorders, correlates with clinical presentation, and
tracks disease progression. Its implementation has the potential to enhance MSA diagnosis and monitoring in both clinical trials and clinical
practice. The MSAai imaging tool was developed by the team at Vanderbilt University Medical Center as part of the bioMUSE Natural History
Study. The study evaluated the utility of volumetric measures and the MSAai in distinguishing early MSA from other movement-related disorders,
correlating with clinical presentation, and tracking longitudinal changes in brain structure. The study results showed that fluid biomarkers
classified bioMUSE participants into MSA (n=10), Lewy body disorders (n=5; PD or DLB), and -synuclein-negative (n=2) groups. At
baseline, MSA patients had significantly lower LN, brainstem, cerebellum, and MSAai values compared to HC, PD, DLB, and PAF (all p<0.001).
The MSAai demonstrated strong group discrimination, correlated with UMSARS scores ( =-0.46, p=0.038), and predicted clinical progression
( =0.58, p=0.022). Longitudinally, reductions in LN, brainstem, and MSAai volumes were strongly associated with UMSARS progression.
Cutaneous Phosphorylated Alpha-Synuclein Deposition
Informs Autonomic Function in Individuals with Early-Stage Multiple System Atrophy
Presenter: Leah Mann, PhD, Postdoctoral Research
Fellow, Vanderbilt University Medical Center
This poster presentation evaluated 17 participants
from the bioMUSE Natural History Study who met criteria for clinically probable MSA. The study compared -synuclein deposition in
skin at baseline and 12 months later and examined associations between clinical measures and -synuclein quantitation over the year.
The analysis described the relationship between -synuclein and autonomic function and revealed that cutaneous -synuclein
detection may serve as an effective diagnostic biomarker that can additionally track progression of MSA. Importantly, deposition of -synuclein
may confer insight into symptomatology, as higher - synuclein concentration is associated with greater burden of orthostatic symptoms.
In the analysis, 100% (17/17) of patients exhibited detection of phosphorylated -synuclein by skin biopsy. Cutaneous -synuclein
deposition significantly increased (p = 0.042) from baseline (mean = 6.59 4.37) to 12-month follow-up (mean = 7.71
4.22). Deposition at 12-month follow-up was positively correlated with Orthostatic Hypotension Questionnaire (OHQ) and Composite Autonomic
Symptom Score-31 (COMPASS-31) (OHQ: coefficient = 0.579, p = 0.015; COMPASS-31: coefficient = 0.560, p = 0.024).
Presentations will be available on the Alterity
Therapeutics website here.
Alterity's lead candidate, ATH434, is an
oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically
to reduce -synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain in preclinical models.
As an iron chaperone, it has excellent potential to treat Parkinson's disease as well as various Parkinsonian disorders such as
Multiple System Atrophy (MSA). Phase 1 studies have demonstrated the agent is well tolerated and achieved brain levels comparable to efficacious
levels in animal models of MSA. Positive results from the randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients
with MSA demonstrated robust clinical efficacy, target engagement on key biomarkers, and a favorable safety profile. A second Phase 2
open-label biomarker trial in patients with more advanced MSA is ongoing. ATH434 has been granted Fast Track Designation by the U.S. FDA,
and Orphan Drug Designation by the U.S. FDA and the European Commission for the treatment of MSA.
About ATH434-201 Phase 2 Clinical Trial
The ATH434-201 Phase 2 clinical trial is a randomized,
double-blind, placebo-controlled investigation of 12 months treatment with ATH434 in patients with MSA. The study evaluated the efficacy,
safety and pharmacokinetics of ATH434 as well as the effect of ATH434 on neuroimaging and protein biomarkers. Wearable sensors were employed
to evaluate motor activities outside of the clinic. The study enrolled 77 adults who were randomly assigned to receive ATH434 50 mg or
75 mg twice daily or matching placebo. The data showed that, compared to placebo, ATH434 produced clinically and statistically significant
improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, a functional rating scale that assesses
disability on activities of daily living affected in MSA. Additional efficacy assessments demonstrated improvement consistent with the
positive UMSARS Part I findings including trends in improved motor performance on the Parkinson's Plus rating scale, the Clinical
Global Impression of Severity Scale, and the Orthostatic Hypotension Symptom Assessment (a patient reported outcome). Wearable sensor
data indicated that ATH434 also led to increased activity in an outpatient setting. Biomarkers were used to evaluate potential drug effect
and target engagement relative to placebo. Both dose levels reduced iron accumulation in MSA affected brain regions with trends in preservation
of brain volume. ATH434 was well tolerated with similar adverse event rates compared to placebo and no serious adverse events attributed
to ATH434. Additional information on the Phase 2 trial can be found by ClinicalTrials.gov
Identifier: NCT05109091.
Biomarkers of progression in Multiple System Atrophy
(bioMUSE) is a natural history study that aims to track the progression of individuals with MSA, a parkinsonian disorder without approved